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The envelope (E) protein of dengue virus (DENV) is composed of three domains (EDI, EDII, EDIII) and is
the main target of neutralizing antibodies. Many monoclonal antibodies that bind EDIII strongly
neutralize DENV. However in vitro studies indicate that anti-EDIII antibodies contribute little to the
neutralizing potency of human DENV-immune serum. In this study, we assess the role of anti-EDIII
antibodies in mouse and human DENV-immune serum in neutralizing or enhancing DENV infection
in mice. We demonstrate that EDIII-depleted human DENV-immune serum was protective against
homologous DENV infection in vivo. Although EDIII-depleted DENV-immune mouse serum demon-
strated decreased neutralization potency in vitro, reduced protection in some organs, and enhanced
disease in vivo, administration of increased volumes of EDIII-depleted serum abrogated these effects.
These data indicate that anti-EDIII antibodies contribute to protection and minimize enhancement
when present, but can be replaced by neutralizing antibodies targeting other epitopes on the dengue
virion.
& 2012 Elsevier Inc. All rights reserved.Introduction
Placing up to half of the world’s population at risk, dengue virus
(DENV) is the most important emerging arboviral pathogen affecting
humans (WHO, 1997). Transmitted by the Aedes aegypti and Aedes
albopictus mosquitoes (Efﬂer et al., 2005; Rodhain and Rosen, 1997),
DENV is comprised of 4 serotypes, DENV1-4 (Burke and Monath,
2001). A large percentage of the estimated 100 million annual
infections are clinically asymptomatic; symptomatic infections range
from the self-limited but debilitating dengue fever (DF) to the
potentially life-threatening dengue hemorrhagic fever and dengue
shock syndrome (DHF/DSS) (Halstead, 2007; Rothman, 2010).
The DENV envelope (E) protein is the major antigenic target on
the surface of the virion (Roehrig et al. 1998). Initial monoclonal
antibody (MAb) mapping studies (reviewed in Roehrig et al. (1998))
identiﬁed the E protein to be composed of three distinct antigenic
regions: A, B and C. Subsequent analysis of the crystal structure of
DENV E glycoprotein revealed three domains – I, II and III – that
were directly comparable with the previously-deﬁned antigenic
regions C, A and B, respectively (Modis et al., 2003; Rey et al.,
1995). Studies with mouse monoclonal antibodies (MAbs) have
determined that antibodies targeting Domains I/II (EDI/II) are gen-
erally more cross-reactive among serotypes and of low to moderate
neutralizing potency (Crill and Chang, 2004; Oliphant et al., 2006).ll rights reserved.In contrast, mouse MAbs binding Domain III (EDIII) are serotype-
speciﬁc and highly neutralizing (Crill and Roehrig, 2001; Gromowski
and Barrett, 2007; Lin et al., 1994; Lok et al., 2008; Sukupolvi-Petty
et al., 2007), although both cross-reactive and non-neutralizing MAbs
binding to newly identiﬁed EDIII epitopes have been identiﬁed
(Shrestha et al., 2010; Sukupolvi-Petty et al., 2010, 2007).
A person exposed to a primary DENV infection develops a
polyclonal antibody response that neutralizes the homologous
serotype responsible for infection, while leaving the subject sus-
ceptible to a second infection with a different serotype (Endy et al.,
2004; Sabin, 1952). Pre-existing cross-reactive antibodies may
enhance a second DENV infection and lead to more severe disease
(Halstead, 2003). Investigators are now beginning to study the
binding and functional properties of human antibodies and to
compare the human response to the well-studied mouse response.
Studies of human sera and MAbs indicate that multiple viral
antigens, including E protein, pre-membrane (prM/M) protein and
non-structural protein 1 (NS1), are recognized by human antibodies
(Beltramello et al., 2010; Crill et al., 2009; de Alwis et al., 2011;
Dejnirattisai et al., 2010; Lai et al., 2008; Schieffelin et al., 2010).
Moreover, most DENV-speciﬁc human antibodies are cross-reactive
and weakly neutralizing, and a minor population of antibody
appears to be responsible for the ability of immune sera to strongly
neutralize the homologous serotype (Beltramello et al., 2010; Crill
et al., 2009; de Alwis et al., 2011; Dejnirattisai et al., 2010; Lai et al.,
2008; Schieffelin et al., 2010). Based on studies with mouse MAbs, it
had been assumed that human antibodies that potently neutralize
DENV also bind to EDIII. However, recent data has suggested that
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human anti-DENV antibody repertoire and do not contribute
substantially to in vitro neutralization of DENV (Midgley et al.,
2010; Oliphant et al., 2007; Wahala et al., 2009). Here we investi-
gate the contribution of EDIII-speciﬁc antibodies in mouse and
human DENV-immune serum to DENV protection and enhance-
ment using a mouse model of DENV infection and disease.Fig. 1. Human E Domain III (EDIII) antibodies constitute a small portion of the
polyvalent serum neutralizing antibody response. Human DENV2-immune serum
was obtained from a DENV-immune individual enrolled in the University of
North Carolina dengue traveler study and was subsequently depleted of anti-EDIII
antibodies using either MBP-EDIII (383D) or MBP-control beads. (A) ELISA plates
were coated with DENV2 MBP-EDIII (383D) or MBP protein (negative control).
Undiluted MBP-EDIII-383D- and MBP-depleted human sera were tested for reactivity
against with DENV2 MBP-EDIII (383D), and the absolute OD value at 405 nm is
shown on the y-axis. (B) Neutralization titer against the DENV2 D2S10 strain used
for in vivo infections was measured by a neutralization assay using human U937 DC-
SIGN cells. Relative infection is shown on the x-axis, log reciprocal dilution of the
serum is shown on the y-axis, and a dashed line indicates 50% infection. (C)
Enhancement against the same DENV2 D2S10 strain was measured using K562 cells,
where raw percent infection is measured on the y-axis and log reciprocal serum
dilution is on the x-axis. Each panel is representative of two or three separate
experiments.Results
Human serum depleted of anti-EDIII antibodies reduces viral load
in vivo
Previous studies have demonstrated that humans infected with
DENV develop low levels of anti-EDIII antibodies and that these
antibodies make only a minor (o15%) contribution to the neutra-
lization potency of human immune serum in in vitro assays (Midgley
et al., 2010; Wahala et al., 2009). Thus, we ﬁrst asked whether anti-
EDIII antibodies in human serum contribute to protection in vivo
using a mouse model of DENV infection and disease we had
previously developed (Balsitis et al., 2010; Kyle et al., 2008;
Williams et al., 2009). We obtained a convalescent serum sample
from a person exposed to a primary DENV2 infection and depleted
the serum of anti-EDIII antibodies using a recombinant EDIII-
maltose binding protein (MBP-EDIII) fusion protein or MBP alone
as previously described (Wahala et al., 2009) (Fig. 1A). The neu-
tralizing and enhancing abilities of the MBP-depleted and MBP-
EDIII-depleted serum were assessed using U937 DC-SIGN and K562
ﬂow-cytometry based assays, respectively. MBP-EDIII depletion led
to a 17% reduction in homologous neutralization titer as compared
to the MBP-depleted control (Fig. 1B). Both the MBP-depleted and
MBP-EDIII-depleted samples demonstrated similar peak enhance-
ment titers against DENV2 (422 and 359, respectively) (Fig. 1C).
Taken together, these data support previously published work
(Midgley et al., 2010; Wahala et al., 2009) and indicate that depletion
of anti-EDIII antibodies from human serum does not drastically alter
either the in vitro neutralization or enhancement proﬁles.
While depletion of anti-EDIII antibodies only decreased the
in vitro neutralization titer of the human immune serum by 17%,
it is conceivable these antibodies might be required for protection
in vivo. To test this possibility, experiments were performed using
a recently developed mouse model of DENV infection and disease
(Balsitis et al., 2010; Kyle et al., 2008; Williams et al., 2009).
Seventy microliters of MBP-depleted or MBP-EDIII-depleted
serum was transferred into AG129 mice (n¼5 per group) 24 h
prior to an infection with 103 pfu of DENV2 D2S10, a dose at
which morbidity is not observed but reduction in viremia and
tissue viral load can be measured (Fig. 2A). Non-terminal bleeds
were collected 4–6 h prior to infection to measure circulating
anti-DENV antibody titers. As demonstrated in Fig. 2A, the average
NT50 titer for MBP-depleted and MBP-EDIII-depleted groups were
not signiﬁcantly different from each other, but both were sig-
niﬁcantly higher than the normal human serum (NHS) recipient
mice. Serum viremia and tissue viral load levels were subse-
quently measured 4 days post-infection by either plaque assay or
quantitative RT-PCR. Mice receiving either MBP-depleted or MBP-
EDIII-depleted serum displayed viremia levels that were at or
slightly above the limit of detection for the assay (1 pfu(eq)/mL)
and were signiﬁcantly lower than the NHS-recipient group
(Fig. 2C). Viral load levels were further measured in primary and
secondary lymphoid organs; signiﬁcant reductions in the spleen
and bone marrow were observed in both experimental groups, as
compared to the NHS control (Fig. 2D and E). Importantly, across
all organs tested, there was no difference in serum viremia or
tissue viral load between the MBP-depleted and MBP-EDIII-depleted groups. These data indicate that anti-EDIII antibodies in
human serum were not required for protection observed in vivo.
Mice infected with DENV develop anti-EDIII antibodies that
contribute to neutralization but not enhancement in vitro
Previous data have suggested that most mouse MAbs that
strongly neutralize DENV bind to EDIII (Sukupolvi-Petty et al.,
2007). Thus, we next examined whether mice exposed to DENV
infection develop a polyclonal neutralizing antibody response that
is mainly directed against epitopes on EDIII. We depleted pooled
anti-DENV2 mouse serum with MBP-EDIII protein using the same
approach described for human immune sera (Wahala et al., 2009).
Fig. 2. Human anti-EDIII antibodies are not required for protection in vivo. AG129 mice (n¼5 per group) were administered 70 ml of either human MBP-depleted (‘‘MBP’’)
or MBP-EDIII-depleted (‘‘MBP-EDIII’’) DENV2 immune serum or non-immune human serum (‘‘NHS’’) 24 h prior to infection with 103 pfu of D2S10 iv. (A) Retro-orbital eye-
bleeds were taken 4–6 h prior to DENV infection, and circulating neutralizing antibodies were measured against the infecting virus. The dashed line indicates the limit of
detection for the assay. (B–D) Animals were sacriﬁced 4 days post-infection, and viral load was measured in the serum (B), spleen (C), and bone marrow (D). The data
points presented here are combined from two separate experiments. In each graph B–D, the x-axis is the limit of detection. *p-value o0.05 as compared to NHS; **p-value
o0.01 as compared to NHS.
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EDIII-speciﬁc ELISA and demonstrated that there was negligible
measurable binding to the MBP-EDIII protein in depleted serum
(Fig. 3A).
Having removed the EDIII-speciﬁc antibodies from the anti-
DENV2 serum, we measured the contribution of anti-EDIII antibo-
dies to homologous neutralization and enhancement in vitro. A 34%
reduction in homologous neutralization titer was observed compar-
ing MBP-EDIII-depleted serum to MBP-depleted serum (Fig. 3B). The
MBP-depleted and MBP-EDIII-depleted serum demonstrated similar
peak enhancement titers (397 and 360, respectively) against DENV2
(Fig. 2C). Our data indicate that mice make EDIII-speciﬁc antibodies
that contribute more signiﬁcantly to in vitro neutralization than do
human anti-EDIII antibodies. Nonetheless, more than half the
neutralizing antibodies in mice are not directed against EDIII.
EDIII-depleted anti-DENV2 mouse serum can protect against
DENV2 infection
As our in vitro analysis of the MBP-EDIII-depleted serum
indicated that EDIII-speciﬁc mouse antibodies contributed 34% to
the overall neutralizing potency of DENV2-immune serum, we
next asked whether MBP-EDIII-depleted serum would be as
protective in vivo as control-depleted serum. Similarly to the
experiments described using human immune serum, anti-DENV
immune mouse serum was transferred 24 h prior to a sublethal
103 pfu infection, and non-terminal bleeds were taken 4–6 h prior
to infection to measure the neutralizing titer of the circulating
anti-DENV antibodies present at the time of infection (Fig. 4A).We ﬁrst transferred equivalent volumes of MBP-depleted (MBP)
and MBP-EDIII-depleted (MBP-EDIII-A) serum (n¼4–6 per group)
such that the average neutralization titer of the transferred serum
in vivo was 67.4 and 47, respectively (Fig. 4B) and signiﬁcantly
higher than NMS-recipient mice (po0.01 for both comparisons).
As the difference between the MBP-depleted and MBP-EDIII-
depleted serum was 34% in vitro, we expected to see a comparable
difference following transfer in vivo; indeed, comparing the
average NT50 titers between the MBP (67.4) and MBP-EDIII-A
(47) groups yielded a difference of 30%. Serum viremia levels in
mice administered either MBP or MBP-EDIII-A serum were sig-
niﬁcantly reduced as compared to NMS-recipient mice (p¼0.015,
MBP and p¼0.014, MBP-EDIII-A) (Fig. 4C); however, the viremia
levels were not signiﬁcantly different from each other. In the
primary and secondary lymphoid organs, the mice administered
either MBP or MBP-EDIII-A immune serum showed signiﬁcant
reductions in viral load as compared to the NMS-recipient groups
(Fig. 4D–F). In the lymph node, the animals receiving MBP-EDIII-A
depleted serum had statistically elevated titers as compared to the
MBP group (p¼0.0285) while both groups demonstrated reduced
viral loads as compared to NMS-recipient mice (Fig. 4E).
We next assessed whether MBP-EDIII-depleted serum transferred
at equivalent neutralizing titer (MBP-EDIII-B) as MBP-depleted
serum (MBP) would be more protective than MBP-EDIII-depleted
serum of lower in vivo neutralizing titer (MBP-EDIII-A). From the
in vitro neutralization titers, we determined that in order to transfer
MBP-EDIII-depleted serum of equivalent neutralizing capacity, we
had to increase the volume of MBP-EDIII-depleted serum adminis-
tered prior to D2S10 infection by approximately one third. Thus,
Fig. 3. Mouse anti-EDIII antibodies contribute to serotype-speciﬁc neutralization
but not enhancement in vitro. Pooled anti-DENV2 PL046 serum was collected 6–8
weeks following intra-peritoneal infection of AG129 mice and was depleted of
anti-EDIII antibodies using MBP-EDIII (383E) or control MBP protein. (A) ELISA
plates were coated with DENV2 MBP-EDIII (383E) and MBP protein (negative
control). Undiluted MBP-EDIII- and MBP-depleted mouse sera were tested for
reactivity with DENV2 MBP-EDIII (383E), and absolute OD value at 405 nm is
shown on the y-axis. (B) Neutralization titer against the DENV2 D2S10 strain used
for in vivo infections was measured by neutralization assay in U937 DC-SIGN cells.
Relative infection is shown on the x-axis, the log reciprocal dilution of the serum is
shown on the y-axis, and a dashed line indicates 50% infection. (C) Enhancement
against DENV2 D2S10 was measured in K562 cells, where raw percent infection is
shown on the y-axis and log reciprocal serum dilution is shown on the x-axis. Each
panel is representative of two or three separate experiments.
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such that the average NT50 titer of the circulating antibodies was 63
(Fig. 4B) and comparable to animals receiving MBP-depleted serum
(MBP, average NT50¼67). Animals receiving MBP-EDIII-B serum had
signiﬁcantly reduced viral loads as compared to NMS-recipient mice,
and a reduction in viral load was observed in the lymph node
(p¼0.055; Fig. 4E) and bone marrow (p¼0.13, Fig. 4F) as compared
to MBP-EDIII-A recipient mice. There was no difference in viral load
comparing the MBP-EDIII-B to the MBP recipient mice. These data
demonstrate that even in the absence of anti-EDIII antibodies,
homologous serum is still potently neutralizing and capable of
serotype-speciﬁc reduction in viral load. Taken together, we concludethat anti-EDIII antibodies, when present, contribute to neutralization
in vitro and protection in vivo, but are not required.
Neutralization titer, rather than antibody repertoire of
DENV-immune serum, is a better in vitro correlate of
enhancement in vivo
Infection with one serotype of DENV is expected to confer life-
long immunity against the same serotype (Innis, 1997; Sabin,
1952). In contrast, a second infection with a different serotype is
the greatest risk factor associated with the development of severe
disease (Halstead, 2003). As the anti-EDIII antibodies do not
appear to contribute substantially to in vivo protection, we next
hypothesized that they may be a key component in preventing
homologous enhancement. To test this hypothesis, AG129 mice
(n¼3–5 per group) were administered equivalent volumes of
either MBP-depleted or MBP-EDIII-depleted serum or NMS. Pre-
infection bleeds were taken 4–6 h prior to infection to measure
the circulating antibody titers by neutralization assay (NT50 titer).
As in the protection experiment, the average NT50 titer of the
MBP-EDIII-A group (54) was approximately one-third (28%) lower
than that of the MBP group (74.5). A fourth group of mice received
MBP-EDIII-depleted serum of equivalent neutralizing potency
(MBP-EDIII-B, average NT50¼75) as the MBP group. The control
group of mice receiving NMS did not have a measurable NT50 titer
(Fig. 5A, Table 1).
Mice were infected 24 h following serum transfer with 104 pfu
DENV2 D2S10, a sublethal dose that can be lethal under enhan-
cing antibody conditions, and were followed for morbidity and
mortality. Only 1/4 of the animals receiving the MBP-depleted
serum developed transient signs of disease (0.5 day in duration).
In contrast, 3/4 of the animals receiving the same volume of
MBP-EDIII-depleted serum (MBP-EDIII-A) all developed severe
signs of disease and died by Day 5 (p¼0.043 as compared to
MBP-depleted serum control) (Fig. 5B, Table 1). These data
validate previously published results identifying a reciprocal
relationship between neutralization titer and risk of homologous
enhancement in vivo (Balsitis et al., 2010).
To determine whether an increase in neutralization titer of the
MBP-EDIII-depleted serum would be sufﬁcient to abrogate this
enhancement response, we transferred sufﬁcient volumes of
MBP-EDIII-depleted serum such that the average NT50 titer of
the transferred serum in vivo was 75 (MBP-EDIII-B) and not
signiﬁcantly different from the MBP-depleted serum recipient
mice (MBP) (Fig. 5A, Table 1). Following a 104 sub-lethal D2S10
infection, none of the three animals receiving the increased
volume of MBP-EDIII-depleted serum demonstrated signs or
symptoms of illness (p¼0.075 as compared to the MBP-EDIII-A
group) (Fig. 5B, Table 1). These data support a relationship
between decreased neutralization titer and increased risk of
enhancement and further conﬁrm that the risk of enhancement
is minimized upon transfer of either control-depleted or MBP-
EDIII-depleted serum of equivalent neutralizing titer. Further, as
the increased volume of MBP-EDIII-B serum was determined
based on the neutralization titer measured in vitro prior to
transfer in vivo, these data further validate the relationship
between in vitro neutralization titer and homologous enhance-
ment in vivo.Discussion
Many mouse MAbs that strongly neutralize DENV and other
ﬂaviviruses bind to well-deﬁned epitopes on Domain III of the
viral envelope protein. The objective of this study was to deter-
mine whether anti-EDIII antibodies were responsible for potent
Fig. 4. Murine EDIII-speciﬁc antibodies contribute slightly to protection in vivo. (A) Schematic of the anti-DENV2 MBP-EDIII-depletion and in vivo experimental design.
DENV2-immune serum was generated 6 weeks post-infection and serum pooled prior to depletion. AG129 mice (n¼3–5/group) were administered either 250 ml of
MBP-depleted serum (MBP), 250 ml (MBP-EDIII (A)) or 400 ml (MBP-EDIII (B)) of EDIII-depleted serum, or 400 ml non-immune mouse serum (NMS) 24 h prior to infection
with 103 pfu of D2S10 iv. (B) Sub-mandibular bleeds were taken 4–6 h prior to infection, and circulating anti-DENV neutralizing antibodies were measured against the
infecting virus. The dashed line indicates the limit of detection for the assay. (C–E) Animals were sacriﬁced 4 days post-infection, and viral load was measured in the serum
(C), bone marrow (D), lymph node (E), and spleen (F). The data points presented are combined from two separate experiments except for MBP-EDIII (B) which could only
be performed once due to limited volumes of serum available. In each graph C–F, the x-axis indicates the limit of detection. *p-value o0.05 as compared to NMS; **p-value
o0.01 as compared to NMS; yp-value o0.05 as compared to MBP-EDIII (A); yyp-value¼0.055 as compared to MBP–EDIII (A).
K.L. Williams et al. / Virology 429 (2012) 12–2016neutralizing activity in immune sera from mice and humans
exposed to DENV infection. Thus, the role of anti-EDIII antibodies
in mouse and human immune sera were studied using in vitro
cell culture models and an in vivomouse model of DENV infection
and disease.
Our initial observations studying human serum conﬁrm pre-
viously published results that anti-EDIII antibodies constitute
between 5% and 15% of the serotype-speciﬁc neutralizing titer
measured in vitro (Midgley et al., 2010; Wahala et al., 2009).
As suggested by the in vitro neutralization studies, anti-EDIII-
depleted human serum was as protective as control-depletedserum when tested in vivo. These data additionally validate the
ability of human immune serum to mediate robust protection
against DENV infection in a mouse model. To further investigate
the role of anti-EDIII antibodies in modulating protection in vivo,
we turned to anti-DENV-immune mouse serum, where we found
that anti-EDIII antibodies contributed 34% to in vitro serotype-
speciﬁc neutralization. Following in vivo transfer, the difference in
average neutralizing potency between the control-depleted and
MBP-EDIII-depleted (MBP-EDIII-A) groups (measured ex vivo) was
30%, thus mirroring the difference in serum NT50 titer measured
in vitro prior to transfer. While we observed a signiﬁcant increase
Fig. 5. Anti-EDIII antibodies prevent enhancement in vivo. AG129 mice (n¼3–5/
group) were administered 250 ml of MBP-depleted serum (MBP) or 250 ml (MBP-EDIII
(A)) or 400 ml (MBP-EDIII (B)) of EDIII-depleted serum, or 400 ml of non-immune
mouse serum (NMS) prior to a sublethal infection with 104 pfu of DENV2 D2S10 iv.
See schematic in Fig. 4A for details. (A) Twenty-four hours prior to infection, sub-
mandibular bleeds were taken and the serumwas used tomeasure neutralization titer
in U937 DC-SIGN cells. The dashed line indicates the limit of detection for the assay.
(B) Animals were followed for morbidity and mortality for 10 days following infection.
Survival outcome is depicted in a Kaplan–Meier survival curve. The data points
presented are combined from two separate experiments, except for the MBP–EDIII
(A) and MBP-EDIII (B) conditions, which could only be tested once due to limited
volumes of serum available. *p-value o0.05 as compared to NMS; **p-value o0.01 as
compared to NMS; yp-value o0.05 as compared to MBP-EDIII (A); yyp-value¼0.075 as
compared to MBP-EDIII (A).
Table 1
Neutralizing Titer
(NT50 Mean7sd)
Morbidity Mortality Mortality
p-valuen
NMS 1070 0/5 0/5 0.025
MBP 74.5721 1/4 0/4 0.043
EDIII-A 53.878 3/4 3/4 –
EDIII-B 7574 0/3 0/3 0.075
n p-value calculated in comparison to EDIII-A.
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MBP-EDIII-depleted (MBP-EDIII-A) as compared to control-
depleted serum, there was little to no difference in viral burden
between the two groups in the serum or spleen.
The organ-speciﬁc differences observed while measuring pro-
tection may be explained in that initial interactions between
antibody and virus would ﬁrst occur in the serum and quickly
thereafter in the spleen, which acts as a direct ﬁlter for the blood.
However, trafﬁcking of antibody to and DENV infection of the
lymph node and bone marrow is more complicated. Different
trafﬁcking routes required for both the antibody (transferred i.p.)
and virus (infected i.v.) to cross the blood-tissue barrier, as well as
the potential requirement for active migration of antigen-present-
ing cells containing infectious virus may jointly contribute to the
differences observed in the lymph node and bone marrow
(Alvarezet al., 2008; von Andrian and Mempel, 2003). For instance,studies of the infection kinetics of DENV2 D2S10 demonstrate that
replicating virus appears 24 h earlier in the spleen (day 2) than
lymph node (day 3) (Kyle et al., 2008) these organ-speciﬁc
infection kinetics may further explain the differences in protection
observed between the MBP- and MBP-EDIII-A-depleted experi-
mental groups. Robust protection in all organs was re-established
when MBP-EDIII-depleted (MBP-EDIII-B) serum was transferred at
an increased volume (400 ml) to compensate for the marginal loss
in neutralizing titer, indicating that the differences observed
between viral titers in lymph node and spleen are due to
differences in the neutralizing potency, rather than EDIII-binding
speciﬁcity, of the polyvalent serum. Taken together, these data
indicate that mouse anti-EDIII antibodies are responsible for
approximately one third of in vitro serum neutralizing potency,
but the reduction in neutralization potency resulting from deple-
tion of anti-EDIII antibodies confers only a small loss of protection
in vivo. Furthermore, complete protection can be re-established
following transfer of an increased volume of additional MBP-EDIII-
depleted serum, indicating that anti-EDIII antibodies per se are not
required for homologous protection in vivo.
These results indicate that while the neutralizing antibody
response may be more skewed towards EDIII-speciﬁc antibodies
in mice than in humans, the anti-EDIII antibodies are not critical
for in vivo protection. This ﬁnding is intriguing, as MAb studies
have frequently isolated strongly neutralizing, EDIII-speciﬁc anti-
bodies from mice (Lin et al., 1994; Roehrig et al., 1998; Shrestha
et al., 2010; Sukupolvi-Petty et al., 2010), whereas such MAbs are
present but rare in humans (Beltramello et al., 2010; Crill et al.,
2009; de Alwis et al., 2011; Dejnirattisai et al., 2010; Lai et al.,
2008; Schieffelin et al., 2010). These observations may be
explained in that the strongly neutralizing anti-EDIII murine
antibodies often resulted from a multi-tiered vaccination strategy
using recombinant E protein or EDIII alone as the primary
immunogen or as a ﬁnal boost (Shrestha et al., 2010; Sukupolvi-
Petty et al., 2010). In contrast, our DENV-immune mouse serum
was generated following only one infection (i.p. route) with live
DENV, similar to a natural primary DENV infection in humans.
Further, the serum was collected between 6 and 8 weeks post-
infection, consistent with a time frame when the anti-EDIII anti-
body response should be fully developed (Oliphant et al., 2007). In
agreement with observations that both murine and human anti-
bodies can bind outside EDIII and potently neutralize DENV and
other ﬂaviviruses (Gromowski et al., 2008; Roehriget al., 1998;
Sukupolvi-Petty et al., 2010), our data supports a model in which
non-EDIII antibodies are sufﬁcient to mediate robust protection in
the absence of anti-EDIII antibodies.
Although only small changes in protection were observed when
equivalent volumes of intact versusMBP-EDIII-depleted serumwere
transferred in vivo, clear phenotypic differences in in vivo outcome
were observed when the animals were challenged with an enhan-
cing dose of DENV2. Similar to the protection experiment, a 30%
reduction was observed when comparing the average NT50 titer
between the MBP- and MBP-EDIII-depleted (MBP-EDIII-A) groups;
however, this difference was not statistically signiﬁcant. None-
theless, 75% of animals receiving MBP-EDIII-depleted (MBP-EDIII-
A) serum succumbed, while none of the mice receiving MBP-
depleted control serum died. These data suggest that both antibody
composition and neutralizing potency of transferred serum may be
important factors in preventing enhancement of homologous infec-
tion. However, increasing the NT50 titer of the MBP-EDIII-depleted
(MBP-EDIII-B) serum to an average titer identical to control, MBP-
depleted serum eliminated enhancement in vivo, implying that
neutralizing potency, rather than antibody composition of the
transferred serum, was the more important correlate of enhance-
ment in vivo. These data support previous observations that anti-
DENV2 mouse serum enhanced a DENV2 D2S10 infection in the
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(Balsitis et al., 2010). Further, observations in human
maternal—infant clinical studies have similarly suggested a rela-
tionship between reduced neutralization titers against the infecting
serotype and development of severe disease (Chau et al., 2009;
Kliks et al., 1988; Libraty et al., 2009).
Given the ability of anti-EDIII antibodies to contribute robustly
to homologous protection with minimal cross-reactive binding,
recombinant EDIII protein has been proposed as a vaccine
candidate (Block et al., 2010; Valdes et al., 2009, 2011). In initial
studies using a novel capsid-EDIII recombinant fusion protein,
Valdes et al. (2009) demonstrated a measurable humoral and
cellular immune response; when the protein was used to boost a
homologous infection, the antibody response was both potent and
long-lasting (Valdes et al., 2011). In a separate set of experiments,
Block et al. (2010) tested a similar hypothesis using an insect cell-
derived, recombinant EDIII-based protein vaccine and found that
vaccination of mice with tetravalent EDIII protein produced
antibodies that exhibited both neutralizing and enhancing activ-
ity. However, the enhancing activity of the antibodies generated
following EDIII vaccination spanned a much smaller range of
serum dilutions than comparable polyvalent mouse serum gen-
erated from a DENV infection (Block et al., 2010).
One potential limitation of this study is the passive transfer of
human immune serum into mice. While the interactions between
human IgG and mouse Fcg receptor (FcgR) are not identical
in either speciﬁcity or strength of binding (Nimmerjahn and
Ravetch, 2008), human IgG has been shown to bind to relevant
mouse FcgRs (Ravetch and Anderson, 1990). Further, passive
transfer into mice of human serum generated following vaccina-
tion with the 1976 swine ﬂu vaccine has been employed to study
cross-reactive protection against H1N1 inﬂuenza infection (Xie
et al., 2011). Additionally, experiments studying the development
of active immunity to tick-borne encephalitis virus (TBEV) in the
presence of either human or mouse TBEV-immune serum demon-
strated equivalent survival rates and provided further evidence
that human IgG could interact with mouse FcgR in a similar
fashion as mouse IgG (Kreil et al., 1998). Finally, we have
previously shown that human IgG1 monoclonal antibodies 82.11
and 87.1 can enhance sub-lethal infections and cause lethal
disease in the AG129 mouse model, whereas aglycosylated var-
iants incapable of interacting with the FcgR are not (Beltramello
et al., 2010). These two human IgG1 antibodies enhanced disease
at equivalent concentrations and with similar kinetics to chimeric
antibodies generated using the mouse IgG2a Fcg constant region
in place of the human IgG1 Fcg constant region (K. Williams,
M. Beltramello, A. Lanzavecchia, F. Sallusto, E. Harris, unpublished
data). Together, these ﬁndings demonstrate that certain properties
of human sera can be evaluated in a mouse model. Another
potential limitation could be mis-folding of the recombinant
MBP-EDIII used to deplete the sera; however, proper folding of
the recombinant protein used for depletion was conﬁrmed using a
panel of MAbs directed towards critical EDIII epitopes (Wahala
et al., 2009). Nonetheless, it is possible that some antibodies may
bind to oligomeric epitopes that straddle either EDII and EDIII or
EDI and EDIII, such as the recently identiﬁed 5H2 MAb that
includes contact residues in the EDI-EDIII linker (Cockburn et al.,
2011); such antibodies would not be depleted using recombinant
MBP-EDIII.
Using a murine model of DENV infection and disease, we
analyzed the relationship between DENV-immune serum and
disease severity in the absence of additional contributing factors
such as long-lived plasma cells, memory B cells, or the T cell-
mediated immune response, and our ﬁndings indicate that the
components of the antibody repertoire (anti-EDI/II or anti-virion
antibodies) remaining after depletion of EDIII-speciﬁc antibodiesare protective at a sufﬁciently high neutralizing titer. While
neither mice nor humans appear to make large amounts of
functional anti-EDIII antibodies in response to natural infection,
our data suggest that when present, anti-EDIII antibodies help to
reduce viral load and minimize the risk of enhancement. Vaccines
designed to skew the immune response towards highly neutraliz-
ing and serotype-speciﬁc epitopes on the surface of EDIII would
be predicted to be quite efﬁcient in protecting against homotypic
re-infection and minimizing cross-reactive enhancement. Further
evaluation of the correlation between neutralization titer and
disease severity in the context of prospective pediatric and
maternal-antibody cohort studies will complement this work
and contribute to improving the long-term safety and efﬁcacy of
tetravalent DENV vaccines.Materials and methods
Viruses and cell lines
All viruses was propagated in Ae. albopictus cell line C6/36
(American Type Culture Collection) and titered by plaque assay on
baby hamster kidney cells (BHK21, clone 15) (Shresta et al., 2004).
DENV2 D2S10 was derived as described in Shresta et al. (2006).
PL046 was obtained from H.-Y. Lei (National Cheng Kung Uni-
versity, Taiwan). U937 DC-SIGN (A. de Silva, University of North
Carolina, Chapel Hill) and K562 cells were used for neutralization
and enhancement assays, respectively. Both cells lines were
grown in RPMI media (Invitrogen) at 37 1C in 5% CO2.
DENV immune human serum
Convalescent DENV immune sera were obtained from volun-
teers who had experienced natural DENV infections during travel
abroad. The protocol for recruiting and collecting blood samples
from people was approved by the Institutional Review Board of
the University of North Carolina at Chapel Hill. Written informed
consent was obtained from all subjects before collecting blood.
AG129 mouse infections
AG129 mice (van den Broek et al., 1995) were bred at the
University of California, Berkeley. All procedures were pre-
approved and conducted according to UC Berkeley Animal Care
and Use Committee.
Production of mouse anti-DENV serum
AG129 mice were infected intra-peritoneally (i.p.) with 105 pfu
of DENV2 PL046. Six to eight weeks post-infection, mice were
sacriﬁced and whole blood collected by terminal cardiac punc-
ture. Serum was isolated from whole blood by centrifugation,
heat inactivated, and stored at 80 1C.
In vivo protection experiments
AG129 mice were administered either mouse or human anti-
DENV2 immune serum in a ﬁnal volume of 400 ml 24 h prior to
infection with an intra-venous (i.v.) sub-lethal, 103 pfu dose of
DENV2 D2S10. Mice assigned to either the MBP-control or the
MBP-EDIII-A experimental group received 250 ml of anti-DENV2
serum diluted into a ﬁnal volume of 400 ml, and mice assigned
to the MBP-EDIII-B group received 400 ml of undiluted EDIII-
depleted serum. Four to six hours prior to infection, a small retro-
orbital or sub-mandibular bleed was performed and 100 ml of
whole blood obtained and processed to generate serum by high
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sacriﬁced and multiple organs obtained to measure serum vir-
emia and tissue viral load as described below.
In vivo enhancement experiments
AG129 mice were administered either mouse anti-DENV2
immune serum or normal mouse serum (NMS) in a ﬁnal volume
of 400 ml 24 h prior to infection with an i.v. sub-lethal, 104 pfu
dose of DENV2 D2S10. As in the protection experiments, the mice
assigned to the MBP-EDIII-A or MBP-EDIII-B groups received
either 250 or 400 ml of MBP-EDIII-depleted serum, respectively
in a ﬁnal volume of 400 ml. Sub-mandibular bleeds were per-
formed prior to infection as described above to collect serum for
further analysis ex vivo.
Depletion of mouse and human DENV2 immune serum
Recombinant EDIII protein fused to maltose binding protein
(MBP-EDIII) was made as previously described using DENV2
S16803. However, when DENV2 strains S16803 and PL046 (used
to generate anti-DENV serum in vivo) were aligned, we observed
1 amino acid difference in EDIII at residue 383 (Suppl. Fig. 1A),
which has been previously identiﬁed as a putative residue
in the lateral ridge epitope (Sukupolvi-Petty et al., 2007;
Trirawatanapong et al., 1992). Therefore, we generated the single
D383E point mutation in 16803 backbone and re-expressed MBP-
EDIII protein. No difference in binding was observed using an
anti-EDIII non-lateral ridge MAb 12C1 (Wahala et al., 2010)
(Suppl. Fig. 1B), but lateral ridge-speciﬁc MAb 3H5 bound more
efﬁciently to MBP-EDIII-383E than MBP-EDIII-383D (Suppl.
Fig. 1C). Human DENV2-immune serum depleted with MBP-
EDIII-383D did not demonstrate differences in binding ability to
either MBP-EDIII-383D or MBP-EDIII-383E protein (Suppl.
Fig. 1D). However, mouse DENV2-immune serum, raised against
DENV2 PL046 (383E) but depleted with DENV2 S16803 (383D),
did not bind to EDIII-383D but did demonstrate 60% residual
binding to EDIII-383E (Suppl. Fig. 1E). Therefore, we used MBP-
EDIII-383D to deplete human DENV2-immune serum and MBP-
EDIII-383E to deplete mouse DENV2-immune serum (raised
against DENV2 PL046). Anti-EDIII antibodies from mouse and
human sera were depleted according to Wahala et al. (2009) with
minor modiﬁcations. Brieﬂy, 250 ml of amylase resin was coated
with 350 mg of MBP-EDIII or MBP control protein in column
buffer. After washing, the resin was blocked with 8% NHS or
NMS and undiluted DENV2 immune sera were incubated with
MBP-EDIII resin for 1.5 h. Repeated depletion cycles were per-
formed until all of the EDIII-reactive antibodies were removed.
The same serum was depleted in parallel with MBP-coated resin as
a control. Complete depletion of EDIII-reactive antibodies was
conﬁrmed by ELISA as previously described (Wahala et al., 2009).
Quantiﬁcation of virus in tissue by plaque assay and
quantitative RT-PCR
Tissue viral load was measured by plaque assay as previously
described (Shresta et al., 2004) and was expressed as pfu/g in
solid tissue and as pfu/109 cells in bone marrow. Samples of all
tissues were saved in RNA later (Ambion) and RNA extracted
using an RNeasy Mini kit (Qiagen). Serum was generated from
whole blood by centrifugation, and RNA was extracted using a
Qia-Amp Viral Recovery RNA kit (Qiagen). Serum viremia levels
and tissue viral load were measured as described in Balsitis et al.
(2010). Viral load was expressed as either plaque-forming unit
equivalents/mg GAPDH (tissue) or pfu (eq)/mL (serum).In vitro neutralization and enhancement assays
Pre-transfer serum (control or EDIII-depleted serum prior to
administration to mice) or serum obtained from the small bleeds
taken from each mouse 4–6 h prior to infection was subsequently
analyzed for neutralization titer using U937 DC-SIGN cells and
enhancing activity using K562 cells (pre-transfer serum only). In
both assays, serum was diluted either 1:5 (small bleeds) or 1:10
(pre-transfer serum) and titrated using eight 3-fold dilutions prior
to the addition of DENV2 D2S10 virus, followed by a 45-min
incubation. U937 or K562 cells were then infected for 2 h,
washed, and resuspended in RPMI media. Twenty-four hours
(U937 DC-SIGN cells) or 48 h (K562 cells) following infection,
the cells were washed, ﬁxed in 2% paraformaldehyde (Ted Pella,
Inc.), permeabilized with saponin (Sigma Aldrich) and intracellu-
larly stained with 4G2-Alexa488 (Invitrogen). Percent infection
was determined by ﬂow cytometry using the BD LSR-Fortessa
ﬂow cytometer. Relative infection was calculated using the last
dilution of each serum sample (1:21,870) as its own denominator.
NT50 titers were calculated as described in Balsitis et al. (2010).
Peak enhancement titer (PET) was calculated by plotting raw
percent infection on the y-axis and log serum reciprocal dilution
on the x-axis. A Gaussian distribution was used to ﬁt each
enhancement curve, and the amplitude identiﬁed. This data point
was then used to derive the log-reciprocal serum dilution corre-
sponding to the amplitude and was reported as the PET.
Statistical analysis
Nonparametric analysis of neutralization titers, PET, tissue
viral load and serum viremia data were compared using a
Wilcoxon Rank Sum analysis. Time to onset of morbidity was
assessed using a logrank analysis. All data was analyzed in STATA
v10 (College Station, TX).Acknowledgments
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